Cablivi

Cablivi (caplacizumab) is a medication used to manage certain blood clotting disorders. This intravenous or subcutaneous treatment helps reduce the risk of clotting complications.

Cablivi is primarily used to prevent blood clots in adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood disorder. It works by targeting von Willebrand factor, a protein involved in blood clotting. Patients often wonder, 'What is Cablivi used for?' and the answer lies in its ability to manage and reduce the frequency of clotting events in this specific condition.

Common effects of Cablivi may include bleeding or bruising at the injection site. Some users might experience mild to moderate nosebleeds or gum bleeding. These effects are generally mild and temporary, but any persistent or severe symptoms should be discussed with a healthcare provider.

Cablivi should be used with caution in patients with a history of bleeding disorders or those taking other medications that affect blood clotting. It is important to follow the prescribed dosage and administration instructions to minimize the risk of side effects. Always consult a healthcare professional before starting any new medication.

Cablivi may interact with other medications that affect blood clotting, such as anticoagulants or antiplatelet drugs. Alcohol and certain supplements might also influence its effectiveness. Patients should inform their healthcare provider about all medications and supplements they are taking to avoid potential interactions.